Drug Trial Radar · NCT00185211
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
Last checked: Nov 20, 2026Latest source record: Dec 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
468
Actual
Start
Aug 2002
Primary completion
May 2008
Study completion May 2008
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Sep 16, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 48 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will primarily compare the long-term effects of an early and continued treatment with Betaferon/Betaseron (patients who were treated with active medication during the double-blind BENEFIT study) to treatment initiated either after Clinically Definite Multiple Sclerosis (CDMS) has been diagnosed or after two years (those patients who were treated with placebo during the double-blind BENEFIT study). Analyses are based on the integrated data of the initial BENEFIT study and this follow-up study.
Conditions
- Multiple Sclerosis
Interventions
Interferon beta-1b (Betaseron, BAY86-5046)Drug
Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
Interferon beta-1b (Betaseron, BAY86-5046)Drug
Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in TimeTime frame: up to 60 months after start of treatment
- Time to Confirmed Expanded Disability Status Scale (EDSS) Progression Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With Confirmed EDSS Progression at Selected Points in TimeTime frame: up to 60 months after start of treatment
- Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI) at Month 60Time frame: 60 months after start of treatment
Locations
94 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
Graz, Austria
Site not named
Innsbruck, Austria
Site not named
Vienna, Austria
Site not named
Brussels, Belgium
Site not named
Ghent, Belgium
Site not named
Leuven, Belgium
Site not named
Liège, Belgium
Site not named
Calgary, Alberta, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
London, Ontario, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Brno, Czechia
Site not named
Hradec Králové, Czechia
Site not named
Ostrava, Czechia
Site not named
Pilsen, Czechia
Site not named
Prague, Czechia
Site not named
Prague, Czechia
Site not named
Glostrup Municipality, Denmark
Site not named
Helsinki, Finland
Site not named
Kuopio, Finland
Site not named
Oulu, Finland
Site not named
Seinäjoki, Finland
Site not named
Tampere, Finland
Site not named
Turku, Finland
Site not named
Clermont-Ferrand, France
Site not named
Dijon, France
Site not named
Lille, France
Site not named
Nancy, France
Site not named
Nice, France
Site not named
Paris, France
Site not named
Toulouse, France
Site not named
Rennes, Brittany Region, France
Site not named
Bordeaux, Gironde, France
Site not named
Ulm, Baden-Wurttemberg, Germany
Site not named
München, Bavaria, Germany
Site not named
Regensburg, Bavaria, Germany
Site not named
Würzburg, Bavaria, Germany
Site not named
Hennigsdorf, Brandenburg, Germany
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.